Veliparib with frontline chemotherapy and as maintenance in Japanese women with ovarian cancer: a subanalysis of efficacy, safety, and antiemetic use in the phase 3 VELIA trial

BACKGROUND: The phase 3 VELIA trial evaluated veliparib with carboplatin/paclitaxel and as maintenance in patients with high-grade serous ovarian carcinoma. METHODS: Patients with previously untreated stage III–IV high-grade serous ovarian carcinoma were randomized 1:1:1 to control (placebo with car...

Descripción completa

Detalles Bibliográficos
Autores principales: Mizuno, Mika, Ito, Kimihiko, Nakai, Hidekatsu, Kato, Hidenori, Kamiura, Shoji, Ushijima, Kimio, Nagao, Shoji, Takano, Hirokuni, Okadome, Masao, Takekuma, Munetaka, Tokunaga, Hideki, Nagase, Satoru, Aoki, Daisuke, Coleman, Robert L., Nishimura, Yasuko, Ratajczak, Christine K., Hashiba, Hideyuki, Xiong, Hao, Katsumata, Noriyuki, Enomoto, Takayuki, Okamoto, Aikou
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823063/
https://www.ncbi.nlm.nih.gov/pubmed/36534262
http://dx.doi.org/10.1007/s10147-022-02258-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823063/
https://www.ncbi.nlm.nih.gov/pubmed/36534262
http://dx.doi.org/10.1007/s10147-022-02258-x

Ejemplares similares